AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
09/10/26	€0.5240	+1.75%	47,147
08/10/26	€0.5150	-1.34%	242,876
07/10/26	€0.5220	-4.22%	137,266
06/10/26	€0.5450	+1.49%	212,713
05/10/26	€0.5370	-1.29%	112,852

Real-time Euronext Paris

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - AB Science

Company calendar

Market Closed - Euronext Paris 19:55:00 09/10/2026 +04			5-day change	1st Jan Change
0.5240 ^EUR	+1.75%		-3.68%	-65.89%

09-11	Certain Ordinary Shares of AB Science S.A. are subject to a Lock-Up Agreement Ending on 11-SEP-2026.	CI
08-17	AB Science completes settlement and delivery of its private placement

Market Cap	41.93M 46.95M 39M 35.48M 66.98M 4.54B 67.27M 469M 184M 2.32B 176M 172M 7.43B	P/E 2024	-5.88x	P/E 2025	-51.2x
Enterprise Value	51.2M 57.33M 47.63M 43.32M 81.8M 5.55B 82.15M 573M 225M 2.83B 215M 211M 9.08B	EV / Sales 2024	63.5x	EV / Sales 2025	103x
Free-Float	69.03%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Euronext Paris	AB	Real-time
Börse Stuttgart	A8D	Delayed
CBOE	ABp	Real-time
London S.E.	0Q77	Delayed
Deutsche Boerse AG	A8D	Delayed
CBOE	0Q77	Real-time
Tradegate	A8D	Real-time
Boerse Muenchen	A8D	Real-time

09-11	Certain Ordinary Shares of AB Science S.A. are subject to a Lock-Up Agreement Ending on 11-SEP-2026.	CI
08-17	AB Science completes settlement and delivery of its private placement
08-10	AB Science Wraps Up EUR14 Million Private Placements	MT
08-10	AB Science raises €14.2m
07-13	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
07-10	AB Science streamlines its portfolio and refocuses on two molecules
07-10	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
07-08	Stéphane Ledermann takes the helm at AB Science as CEO
07-07	AB Science S.A. Announces Board Changes	CI
07-07	AB Science S.A. Announces CEO Changes	CI
07-03	AB Science S.A. announced that it has received $2.01616 million in funding	CI
07-01	AB Science, successful private placement
07-01	AB Science S.A. announced that it has received ?2.294 million in funding	CI

AB Science Stock

Stocks

AB

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news: AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Price Extremes

Managers and Directors: AB Science

Latest insider transactions

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

10-09	AB Science : Revenues for the first half of 2026 and update on AB Science’s activities	PU
10-09	AB Science today reports its revenues for the first half of 2026 and provides an update on its activities	GL
09-29	AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection	GL
08-17	AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026	GL
08-10	AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million	GL

10-09	AB Science annonce aujourd’hui ses résultats financiers semestriels au 30 juin 2026 et présente un point sur ses activités
10-09	Bourse : ça bouge chez Saint-Laurent (Kering) et BNP Paribas, SpaceX s'attaque aux opérateurs mobiles
10-09	OpenAI plombe l'ambiance et le Nasdaq
10-04	Agenda des résultats de la semaine : PepsiCo lance le marathon trimestriel
10-02	Agenda Zonebourse des résultats de sociétés : semaine du 5 au 9 octobre 2026

1 day	+1.75%
1 week	-3.68%
Current month	-11.19%
1 month	-25.67%
3 months	-28.51%
6 months	-55.97%
Current year	-65.89%

1 week	0.51	0.57
1 month	0.51	0.73
Current year	0.5	1.61
1 year	0.5	1.68
3 years	0.5	4.46
5 years	0.5	13.76
10 years	0.5	21.75

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Stéphane Ledermann CHM	Chairman	-	07/07/2026
Patrick Moussy BRD	Director/Board Member	-	20/09/2011

Date	Insider	Type	Main position	Quantity	% Market Cap.
20/05/26	Alain Moussy	Sell	Chief Executive Officer	-573	0.0009%
09/02/21	Jean-Pierre Kinet	Sell	Founder	14,525	0.0315%
02/02/21	Jean-Pierre Kinet	Sell	Founder	76,104	0.1652%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	+1.75%	-3.68%	-61.81%	-79.04%	46.95M
ELI LILLY AND COMPANY	+0.83%	+3.19%	+41.49%	+103.56%	1,051B
JOHNSON & JOHNSON	+1.93%	+2.11%	+37.08%	+65.09%	630B
ABBVIE INC.	+1.49%	+5.19%	+19.94%	+85.69%	489B
MERCK & CO., INC.	+2.26%	+0.90%	+69.32%	+40.53%	359B
ROCHE HOLDING AG	+1.45%	+3.50%	+23.29%	+41.62%	344B
NOVARTIS AG	+1.17%	+2.37%	+13.47%	+33.64%	272B
ASTRAZENECA PLC	+0.89%	+1.08%	-6.13%	+9.29%	246B
AMGEN INC.	+1.82%	+2.94%	+42.99%	+52.95%	224B
GILEAD SCIENCES, INC.	+2.77%	+4.44%	+29.01%	+98.99%	187B
Average	+1.64%	+1.91%	+20.87%	+45.23%	380.38B
Weighted average by Cap.	+1.47%	+2.44%	+33.35%	+69.01%

	2024	2025
Net sales	1.07M 1.2M 997K 907K 1.71M 116M 1.72M 12M 4.7M 59.23M 4.51M 4.41M 190M	1.17M 1.31M 1.09M 993K 1.88M 127M 1.88M 13.14M 5.15M 64.86M 4.94M 4.83M 208M
Net income	-7.83M -8.77M -7.28M -6.63M -12.51M -849M -12.57M -87.68M -34.35M -433M -32.93M -32.21M -1.39B	-1.56M -1.74M -1.45M -1.32M -2.49M -169M -2.5M -17.43M -6.83M -86.02M -6.55M -6.4M -276M
Net Debt	10.48M 11.74M 9.75M 8.87M 16.75M 1.14B 16.82M 117M 45.99M 579M 44.08M 43.12M 1.86B	9.27M 10.38M 8.62M 7.84M 14.81M 1B 14.88M 104M 40.67M 512M 38.98M 38.13M 1.64B